With a technique called cell painting, Recursion Pharmaceuticals is creating a really big picture of morphology of cells in the body. But that's just the beginning; the really hard part is knowing how ...

Recursion, a biopharma company, uses a data-driven approach to drug discovery, launching four clinical trials and planning a fifth in oncology. Recursion's software platform, the Recursion OS, is used ...

Data structures and algorithms are vital elements in many computing applications. When programmers design and build applications, they need to model the application data. What this data consists of ...

Recursion's share price has dropped in recent weeks due to poor clinical trial data, but its most mature assets are not reflective of its current capabilities. Recursion probably needs to advance 5-10 ...

Boltz-2 is an open-source biomolecular model achieving near-FEP accuracy with 1000x faster predictions for structure and binding affinity. MIT and Recursion have released Boltz-2, the first ...